Wolverine Trading LLC acquired a new position in shares of Bruker (NASDAQ:BRKR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,861 shares of the medical research company’s stock, valued at approximately $201,000.
Several other hedge funds have also added to or reduced their stakes in BRKR. Prudential Financial Inc. grew its holdings in shares of Bruker by 292.8% in the third quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock valued at $16,868,000 after acquiring an additional 422,660 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Bruker by 7.1% in the fourth quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock valued at $177,566,000 after acquiring an additional 341,389 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Bruker by 5.7% in the fourth quarter. Acadian Asset Management LLC now owns 5,229,258 shares of the medical research company’s stock valued at $179,467,000 after acquiring an additional 280,245 shares in the last quarter. Mackenzie Financial Corp bought a new position in shares of Bruker in the fourth quarter valued at approximately $6,142,000. Finally, Citadel Advisors LLC grew its holdings in shares of Bruker by 107.4% in the third quarter. Citadel Advisors LLC now owns 266,256 shares of the medical research company’s stock valued at $7,921,000 after acquiring an additional 137,879 shares in the last quarter. 65.28% of the stock is owned by institutional investors.
Several equities analysts have weighed in on the company. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a report on Friday. Leerink Swann increased their price objective on Bruker from $32.00 to $34.00 and gave the company a “market perform” rating in a report on Friday, February 9th. Morgan Stanley reissued an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a report on Thursday, December 14th. Evercore ISI assumed coverage on Bruker in a report on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 price objective for the company. Finally, Zacks Investment Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the stock. Bruker has an average rating of “Hold” and an average price target of $32.62.
NASDAQ:BRKR opened at $29.12 on Friday. The firm has a market cap of $4,692.68, a price-to-earnings ratio of 24.07, a P/E/G ratio of 2.00 and a beta of 1.12. Bruker has a 1 year low of $21.83 and a 1 year high of $36.53. The company has a current ratio of 2.59, a quick ratio of 1.66 and a debt-to-equity ratio of 0.57.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.02. The firm had revenue of $530.50 million for the quarter, compared to the consensus estimate of $506.74 million. Bruker had a return on equity of 26.68% and a net margin of 4.45%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.46 earnings per share. analysts predict that Bruker will post 1.37 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, March 23rd. Shareholders of record on Tuesday, March 6th were given a dividend of $0.04 per share. The ex-dividend date was Monday, March 5th. This represents a $0.16 annualized dividend and a dividend yield of 0.55%. Bruker’s dividend payout ratio is currently 13.22%.
ILLEGAL ACTIVITY NOTICE: “Wolverine Trading LLC Acquires New Stake in Bruker (BRKR)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/5861-shares-in-bruker-co-brkr-acquired-by-wolverine-trading-llc.html.
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.